Bausch + Lomb CEO Brent Saun­ders search­es for small­er deals while 'di­gest­ing' $1.75B Xi­idra move

In his sec­ond stint as CEO of Bausch + Lomb, Brent Saun­ders has stayed true to his deal­mak­ing rep­u­ta­tion.

Just a few months af­ter tak­ing the helm in March, Saun­ders an­nounced a deal to ac­quire the dry eye drug Xi­idra from No­var­tis for $1.75 bil­lion. The $6.6 bil­lion eye-care spe­cial­ist will now need time to work through that trans­ac­tion, which is ex­pect­ed to close by year’s end, while keep­ing an eye out for small­er deals, Saun­ders told End­points News in a Wednes­day in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER